Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 9—September 2025

CME ACTIVITY - Research

Severe Group A Streptococcus Infection among Children, France, 2022–2024

Montserrat Sierra ColominaComments to Author , Alix Flamant, Guillaume Le Balle, Jérémie F. Cohen, Lionel Berthomieu, Stéphane Leteurtre, Yves Gillet, Etienne Javouhey, Stéphane Bechet, Corinne Levy, Robert Cohen, Agnès Ferroni, Damien Dubois, Miguel Angel Hernandez Martinez, Céline Plainvert, Asmaa Tazi, Camille Brehin, and ISAI Study Group,1
Author affiliation: CHU Toulouse, Toulouse, France (M. Sierra Colomina, G. Le Balle, L. Berthomieu, D. Dubois, C. Brehin); Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France (A. Flamant, J.F. Cohen, A. Ferroni); Lille University, CHU Lille, Lille, France (S. Leteurtre); Groupe Francophone de Réanimation et Urgences Pédiatriques, Lille (S. Leteurtre); CHU Lyon, Lyon, France (Y. Gillet, E. Javouhey); Association Clinique et Thérapeutique du Val de Marne, Créteil, France (S. Bechet, C. Levy); Groupe de Pathologie Infectieuse Pédiatrique, Créteil (R. Cohen); National Reference Centre for Streptococci, Assistance Publique-Hôpitaux de Paris, Paris Centre, Hôpital Cochin, Paris (M.A. Hernandez Martinez, C. Plainvert, A. Tazi)

Main Article

Table 5

Univariate and multivariate analysis of factors associated with major sequelae/death in children with severe group A streptococcus infections, France, 2022–2024*

Category Major sequelae/death No major sequelae/death p value
Univariate analysis
Female sex 14/31 (45) 150/365 (41) 0.668
Viral infection in the 15 days before hospitalization 16/31 (52) 88/365 (24.1) 0.004
Clinical damage 0.094
ENT 8/31 (25.8) 127/365 (34.8)
Pulmonary 11/48 (35.5) 69/365 (18.9)
Osteoarticular 3/31 (9.7) 54/365 (14.8)
Cutaneous 2/31 (6.5) 60/365 (16.4)
Other 7/31 (22.6) 55/365 (15)
PIMCU/PICU admission 22/31 (71) 90/365 (24.7) <0.001
Clindamycin therapy 21/31 (67.7) 148/365 (40.5) 0.003
Intravenous immunoglobulins 6/31 (19.3) 10/355 (2.8) <0.001
Corticosteroidal therapy 5/28 (17.9) 36/356 (10.1) 0.201
Hydrocortisone hemisuccinate for shock 12/29 (41.4) 7/353 (1.9) <0.001
Vasopressive drug
 19/30 (63.3)
 25/343 (7.3)
 <0.001
Multivariate analysis, odds ratio (95% CI)
Corticosteroidal therapy 4.18 (1.27–13.75) 0.018
Hydrocortisone hemisuccinate for shock 6.25 (1.53–25.50) 0.011
Vasopressive drug 11.27 (3.54–35.89)
 <0.001

*Values are no. (%) except as indicated. Boldface indicates significance. ENT, ear-nose-throat; PICU, pediatric intensive care unit; PIMCU, pediatric intermediate care unit.

Main Article

1Additional members who contributed data are listed at the end of this article.

Page created: July 11, 2025
Page updated: August 21, 2025
Page reviewed: August 21, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external